Bruker Announces Senior Operations Management Appointment
News Feb 24, 2012
Bruker Corporation has announced the appointment of Mr. Stephan Westermann as Executive Vice President - Order Execution, Production & Logistics of the Bruker Scientific Instruments (BSI) segment.
Frank Laukien, President and CEO of Bruker Corporation, stated: “We have considered carefully which candidate could be most effective in this important position, and have concluded that Stephan has the right combination of experience with other companies, experience in Europe and in the US, as well as financial and operational experience with two major Bruker divisions. Stephan has the strong drive and good judgment to make sensible changes in production and logistics, as well as in order execution management from quote to acceptance and cash. Everyone at Bruker strongly supports Stephan in further advancing our Operational Excellence initiative, which has achieved good momentum in the last two years under the leadership of Bill Knight.”
Mr. Westermann’s experience and background include:
• Since May 2011, EVP of Operations of Bruker BioSpin division;
• In 2006-2011, CFO of Bruker AXS division, later CFO of Bruker AXS and Bruker BioSpin;
• In 2003-2006, first CFO and then VP of Printing Technology division at Battenfeld Gloucester Engineering Co. in Massachusetts;
• In 1995-2003, Controller of SMS AG in Germany, a manufacturer of metallurgical plant and rolling mill technology solutions;
• In 1995, Masters in Business & Engineering (Diplom Wirtschaftsingenieurwesen).
Stephan Westermann commented: “I am delighted to be given the opportunity to lead Bruker’s operations teams in order to continue to drive gross margin improvements via alignment of processes in Bruker’s global order execution chain. Bruker intends to generate further efficiency gains and expense reductions, as well as reductions in working capital ratios, and we will also pursue selective best-cost sourcing of non-core activities. Moreover, Bruker will continue stream-lining its global supply chain and developing best-cost manufacturing, always with a focus on quality and customer satisfaction.”
As part of this transition, Mr. William Knight has stepped down from his ‘Interim COO’ position in order to focus fully on his responsibilities as Bruker’s Chief Financial Officer.
A New Tactic in the Fight Against Drug-Resistant InfectionsNews
$1 million research grant could lead to life-saving antibiotics.READ MORE
Concept Life Sciences Appoints New Group Head of ToxicologyNews
Appointment supports growth of the Company and expansion of expertise in integrated drug discovery and development.READ MORE
Gyros Protein Technologies Signs Distribution Agreement with Euro DiagnosticaNews
Gyros Protein Technologies becomes distributor of iLite cell-based reporter gene assays for drug development.READ MORE